Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Janux Therapeutics, Inc.NASDAQ: JANX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $11.13M rose 13.1% year over year, ahead of the -1.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Selling, general & admin amounted to 417.7% of revenue in FY2025, up 30.0 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 11 analysts of $93.52M (+123.9%) for the fiscal year ending Dec 2026, a step up from the +1.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.13M+2.6% QoQ
- Last fiscal yearDec 2025
- $41.77M+1.8% YoY
- LTMMar 2026
- $42.56M-1.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 41.77M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- +41.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.77M | +1.8% |
| FY2024 | 2024-12-31 | 41.05M | +57.0% |
| FY2023 | 2023-12-31 | 26.14M | +17.4% |
| FY2022 | 2022-12-31 | 22.26M | +115.5% |
| FY2021 | 2021-12-31 | 10.33M | — |
Selling, General & Admin vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.1% is the 7th highest of 10, against a peer median of +10.2%.
- Selling, general & admin amounts to 196.9% of revenue for JANX, versus a peer median of 61.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Sep 2026 | $64.15M USD | +52.3% | +47.5% | — | |
| LTM Mar 2026 | €53.63M EUR | +14.4% | +12.3% | 143.8% | |
| LTM Mar 2026 | $52.28M USD | -5.2% | +10.5% | — | |
| LTM Sep 2026 | $51.3M USD | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $42.56M USD | -1.1% | +23.3% | 196.9% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $31.1M USD | -1.0% | -11.4% | 87.5% | |
| LTM Mar 2026 | $18.51M USD | +10.2% | +13.1% | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | +10.2% | +12.3% | 61.5% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.64M | 8.61M | 8.08M | 10.59M | 10M |
| Cost of Revenue | 26.24M | 841K | 1.96M | 2.06M | 2.03M |
| Gross Profit | (22.6M) | 7.77M | 6.13M | 8.53M | 7.97M |
| Gross Margin | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| Research & Development | 26.24M | 53.44M | 54.92M | 68.39M | 125.9M |
| Selling, General & Admin | 10.33M | 22.26M | 26.14M | 41.05M | 41.77M |
| Operating Expenses | 10.33M | 74.86M | 79.11M | 107.38M | 165.64M |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| EBITDA | (32.56M) | (62.22M) | (56.34M) | (66.93M) | (111.6M) |
| EBITDA Margin | -895.2% | -722.5% | -697.0% | -632.2% | -1116.0% |
| Operating Income | (32.93M) | (67.09M) | (72.98M) | (98.85M) | (157.67M) |
| Operating Margin | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Interest Income | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 257K | 4.03M | 14.69M | 29.85M | 44.04M |
| Income Before Tax | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Pre-Tax Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Net Margin | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (Basic) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| EPS (Diluted) | (0.79) | (1.52) | (1.32) | (1.28) | (1.83) |
| Weighted Avg Shares | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
| Weighted Avg Shares (Diluted) | 41.24M | 41.47M | 44.02M | 53.75M | 61.97M |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.